Novartis AG / Fougera Pharmaceuticals Inc.

Generic Topical Dermatology

$2.1B US dermatology market 2012 (Sandoz/Novartis cited)

Disease Overview

Generic topical dermatology covers high-volume, low-margin creams, ointments, gels, and lotions used to treat acne, eczema, psoriasis, fungal infections, and other skin conditions. The category is technically demanding because semi-solid formulations are difficult to manufacture and bioequivalence is hard to demonstrate, which historically protected a small group of incumbents with deep formulation know-how.

Competitive Landscape

Sandoz's $1.525B all-cash acquisition of Fougera consolidated a generic topical dermatology market that, from 2007-2014, was structurally dominated by just three manufacturers — Fougera (now Sandoz), Taro Pharmaceutical Industries, and Perrigo — together holding roughly two-thirds of US generic topical script volume. Mylan, Actavis (later Teva), and Glenmark were secondary players. Fougera (45 generics, 200+ SKUs) plus PharmaDerm (17 specialty brands) brought ~$429M in 2011 net sales and $173M EBITDA to Sandoz, putting the combined entity at ~$620M global generic dermatology revenue and #1 position globally and in the US. The FTC required divestiture of four overlapping topical products as a condition of clearance. Strategically, the deal reinforced Sandoz's differentiated-products platform (semi-solids, complex generics) at a moment when plain-vanilla oral generics were commoditizing — an early foreshadowing of the same dermatology concentration that, post-2013, became the centerpiece of the multi-state generic drug price-fixing complaint naming Sandoz, Taro, Perrigo, and others. (Sources: globenewswire.com 2012-05-02; portal.ct.gov antitrust complaint.)